ARTICLE | Emerging Company Profile
Valo: adding tumor antigens to oncolytic viruses
Valo’s platforms use physical interactions for viral display of tumor antigens without genetic engineering
September 13, 2019 6:11 PM UTC
With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies.
Oncolytic viruses kill cancer cells by lysing the cells, and are engineered to amplify antitumor immune responses through expression of immuno-stimulatory genes. ...